Granules India inks MoU with PharmaMatch

Mumbai, 6th December' 06: PharmaMatch B.V. and Granules India Limited are pleased to announce the signing of a Memorandum of Understanding to develop, manufacture and market formulations in the European Market jointly.

This arrangement will kick-off with the transfer of existing marketing authorizations by PharmaMatch to Granules for products like Paracetamol where Granules has the basic and the necessary skill sets to deliver the same. This will use the upcoming finished dosage facility of Granules which is expected to be commissioned and fully operational by May 2007.

Commenting on the development, Mr. Irfan Vazirally, Executive Director, PharmaMatch India, said, "Granules has demonstrated excellent capabilities in pharmaceutical manufacturing and they are counting on their capabilities to take this forward in their new business of finished dosages as well".

Mr. C. Krishna Prasad, Managing Director, Granules India Ltd. said, "PharmaMatch is a renowned finished dosage player in European Union and we expect this relationship to catapult Granules strongly into the European Market. We are expecting this development to expedite the approval process for the finished dosage facility in the European Union".

About PharmaMatch B.V.

PharmaMatch is a Dutch Pharmaceutical Company with a strong customer base in the European Union with relationships with all the major generic players. It is now moving towards strategic alliances with leading Indian companies, which have fully integrated products. PharmaMatch leverages its technical and regulatory expertise to take their partners into the market on a pan-European scale, by successfully navigating multiple regulatory and market requirements.

About Granules India Ltd.

Granules India Ltd. is a fully integrated pharmaceutical formulations manufacturer with the world's largest 'granulation' capacity. The company manufactures several strategic Active Pharmaceutical Ingredients (APIs) and multiple Pharmaceutical Formulation Intermediates (PFIs), which are distributed in 35 countries.

It is foraying into manufacturing of tablets with a capacity of 6 billion tablets per annum. This facility will strengthen its presence in the pharma outsourcing space as it will have capabilities of offering a wide range of products beginning from APIs to finished dosages (coated/uncoated). Please visit us on https://bsmedia.business-standard.comgranulesindia.com.